Catalent Inc. (CTLT) has been in full swing, highlighted by a series of notable market activities. Amidst acquisition speculations, CTLT's selling agreement with Ardena and the sale of its Somerset, NJ Oral Solids Facility occurred. The company received a string of analyst forecast revisions, following due developments around the acquisition by Novo Holdings. However, not everything is sunny as the FTC, US Senator Warren, and consumer groups have raised concerns about the said acquisition, seeking its blockade. Nevertheless, the Catalent stockholders have approved the buyout and CTLT's CEO affirms commitment to continue leading the company after the completion of the deal. Despite the hurdles, Catalent's Q4 earnings and revenue topped estimates contributing positively to the stock performance. It also completed a $25 million expansion of its clinical supply facility in Schorndorf, Germany. Following this eventful period, some investors and analysts predict a potential undervaluation of the Catalent stock by 24%. However, CTLT has also seen a series of share sell-offs by SVP and other executive members that keeps the stock valuation a matter of balance.
Catalent CTLT News Analytics from Tue, 13 Sep 2016 07:00:00 GMT to Sat, 26 Oct 2024 21:28:32 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -5
